Storys aus Zürich

Filtern
  • 04.02.2019 – 08:30

    Loylogic

    Atlasglobal and Loylogic Announce a Strategic Partnership for Akruu

    Zurich (ots) - Members of Atlasglobal's Loyalty Program, Atlasmiles, can now earn additional miles via Loylogic's state-of-the-art collection portal, Akruu. Loylogic, the global leader in e-commerce and e-payment solutions for loyalty programs, and Atlasglobal, a leading Turkish Airline, announce a strategic partnership for Loylogic's cutting edge, co-branded earning solution, Akruu. Through this collaboration, Atlasmiles ...

  • 23.01.2019 – 16:02

    Philogen

    Philogen Announces Collaboration With Celgene

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...

  • 23.01.2019 – 16:01

    Philogen

    Philogen Announces Collaboration

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...

  • 23.01.2019 – 16:01

    Philogen

    Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...